- Traws Pharma filed Form 12b-25 to delay its annual report on Form 10-K for fiscal year ended Dec. 31, 2025.
- Filing delay tied to additional time needed to assess impact of potential financing on financial statements, including going-concern disclosures.
- Management reported no financing agreement in place as it works to address Nasdaq minimum stockholders’ equity requirement.
- Company expects to file Form 10-K within 15-day extension period allowed under SEC rules.
- Preliminary results point to revenue of $2.8 million; net income seen at about $9.2 million.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Traws Pharma Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001130598-26-000002), on March 31, 2026, and is solely responsible for the information contained therein.
Comments